Tag Archives: targeted therapy
“Best Treatment First”: Implications for front-Loading Combinations in Lung Cancer (BMIC-063)
Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer are best served by receiving the best agents up front, a strategy that implies a value in integrating more treatments into early combos. (9:08)
Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)
Dr. Jack West reviews general principles for how local therapies are increasingly appropriate for selected patients with advanced NSCLC, whether at initial management, for limited progression on systemic therapy, or as local consolidation therapy. (15:36)
Should Osimertinib Become First-Line Treatment of Choice for EGFR Mutation-Positive Advanced NSCLC, or Should it Be Saved for Later? (BMIC-017)
Dr. Jack West reviews the pros and cons of using osimertinib first line vs. “saving” it as a second line therapy, trying to determine the optimal sequence for EGFR-directed therapy in advanced EGFR mutation-positive NSCLC. (11:46)
Dacomitinib: Dark Horse EGFR TKI Charges into a Crowded First Line Setting for EGFR Mutation-Positive Advanced NSCLC (BMIC-016)
Dr. Jack West reviews the results of the ARCHER-1050 trial that showed superior efficacy with dacomitinib vs. gefitinib in EGFR mutation-positive NSCLC. Is it too little, too late for dacomitinib, or can it find a place in a crowded first line setting? (7:53)